These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 17724835)

  • 21. Economic effect of augmentation strategies in patients with type 2 diabetes initiated on sulfonylureas.
    Kalsekar I; Latran M
    Manag Care Interface; 2007 Sep; 20(9):39-46. PubMed ID: 18161391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Balancing risk and benefit with oral hypoglycemic drugs.
    Hamnvik OP; McMahon GT
    Mt Sinai J Med; 2009 Jun; 76(3):234-43. PubMed ID: 19421967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies.
    Penfornis A; Borot S; Raccah D
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S78-90. PubMed ID: 18640590
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
    Raskin P
    Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of patients with type 2 diabetes mellitus with pioglitazone. A survey of a Cochrane review].
    Madsbad S
    Ugeskr Laeger; 2007 Nov; 169(47):4054-7. PubMed ID: 18078659
    [No Abstract]   [Full Text] [Related]  

  • 27. New treatments for diabetes.
    Raz I; Eldor R
    N Engl J Med; 2007 May; 356(21):2222; author reply 2222-3. PubMed ID: 17526096
    [No Abstract]   [Full Text] [Related]  

  • 28. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes.
    Iliadis F; Kadoglou NP; Hatzitolios A; Karamouzis M; Alevizos M; Karamitsos D
    In Vivo; 2007; 21(6):1107-14. PubMed ID: 18210765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pioglitazone in evaluation by IQWiG (Institute for Quality and Cost Effectiveness in Public Health)--tunnel vision instead of broad view].
    MMW Fortschr Med; 2008 Aug; 150(32-35):56-7. PubMed ID: 19009700
    [No Abstract]   [Full Text] [Related]  

  • 30. Choosing first-line therapy for management of type 2 diabetes.
    Graber MA; Darby-Stewart A; Dachs R
    Am Fam Physician; 2008 Jan; 77(1):16-7. PubMed ID: 18236820
    [No Abstract]   [Full Text] [Related]  

  • 31. Massive bilateral pleural effusion associated with use of pioglitazone.
    Chen YW; Chen YC; Wu CJ; Chen HH
    Clin Ther; 2008 Aug; 30(8):1485-9. PubMed ID: 18803990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
    Misbin RI
    Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
    [No Abstract]   [Full Text] [Related]  

  • 34. Metformin--the gold standard in type 2 diabetes: what does the evidence tell us?
    Bosi E
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():3-8. PubMed ID: 19385978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European drug agency extends review of safety of pioglitazone.
    Moynihan R
    BMJ; 2011 Jun; 342():d4105. PubMed ID: 21715461
    [No Abstract]   [Full Text] [Related]  

  • 38. [Progress in therapy for diabetes mellitus--insulin-resistance ameliorating agents].
    Kaku K
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):742-9. PubMed ID: 19472525
    [No Abstract]   [Full Text] [Related]  

  • 39. Preventing type 2 diabetes with low-dose combinations.
    Buchanan TA; Xiang AH
    Lancet; 2010 Jul; 376(9735):72-4. PubMed ID: 20605203
    [No Abstract]   [Full Text] [Related]  

  • 40. Is rationale to decrease serum osteoprotegerin and fetuin-A in type 2 diabetes mellitus patients?
    Berezin A
    Diabetes Metab Syndr; 2016; 10(3):169-70. PubMed ID: 26869171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.